These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 15925560

  • 1. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches.
    Gullestad L, Aukrust P.
    Am J Cardiol; 2005 Jun 06; 95(11A):17C-23C; discussion 38C-40C. PubMed ID: 15925560
    [Abstract] [Full Text] [Related]

  • 2. The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets.
    Gullestad L, Aukrust P.
    Heart Fail Monit; 2001 Jun 06; 2(1):8-13. PubMed ID: 12634893
    [Abstract] [Full Text] [Related]

  • 3. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.
    Aukrust P, Yndestad A, Damås JK, Gullestad L.
    Autoimmun Rev; 2004 Mar 06; 3(3):221-7. PubMed ID: 15110235
    [Abstract] [Full Text] [Related]

  • 4. Anti-inflammatory trials in chronic heart failure.
    Aukrust P, Yndestad A, Ueland T, Damås JK, Gullestad L.
    Heart Fail Monit; 2006 Mar 06; 5(1):2-9. PubMed ID: 16547529
    [Abstract] [Full Text] [Related]

  • 5. Targeted anticytokine therapy and the failing heart.
    Mann DL.
    Am J Cardiol; 2005 Jun 06; 95(11A):9C-16C; discussion 38C-40C. PubMed ID: 15925559
    [Abstract] [Full Text] [Related]

  • 6. Inflammatory cytokines in heart failure: mediators and markers.
    Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P.
    Cardiology; 2012 Jun 06; 122(1):23-35. PubMed ID: 22699305
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Therapeutic potential of anticytokine therapy in congestive heart failure.
    Aukrust P, Yndestad A, Damås JK, Gullestad L.
    Am J Cardiovasc Drugs; 2004 Jun 06; 4(3):169-77. PubMed ID: 15134469
    [Abstract] [Full Text] [Related]

  • 9. The role of intravenous immunoglobulin in the treatment of chronic heart failure.
    Aukrust P, Yndestad A, Ueland T, Damås JK, Frøland SS, Gullestad L.
    Int J Cardiol; 2006 Sep 10; 112(1):40-5. PubMed ID: 16893578
    [Abstract] [Full Text] [Related]

  • 10. [Immunactivation in chronic heart failure. Inflammatory mediators].
    Genth-Zotz S, von Haehling S, Blankenberg S.
    Z Kardiol; 2004 Sep 10; 93 Suppl 4():IV24-30. PubMed ID: 15085363
    [Abstract] [Full Text] [Related]

  • 11. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure.
    Gong K, Zhang Z, Sun X, Zhang X, Li A, Yan J, Luo Q, Gao Y, Feng Y.
    Am Heart J; 2006 Jan 10; 151(1):62-8. PubMed ID: 16368293
    [Abstract] [Full Text] [Related]

  • 12. Immune activation in chronic heart failure.
    Torre-Amione G.
    Am J Cardiol; 2005 Jun 06; 95(11A):3C-8C; discussion 38C-40C. PubMed ID: 15925558
    [Abstract] [Full Text] [Related]

  • 13. Inflammatory mediators in Chinese patients with congestive heart failure.
    Wang Y, Zhou Y, Meng L, Lu X, Ou N, Li X.
    J Clin Pharmacol; 2009 May 06; 49(5):591-9. PubMed ID: 19398605
    [Abstract] [Full Text] [Related]

  • 14. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
    Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H.
    Int J Cardiol; 2005 Aug 18; 103(2):182-6. PubMed ID: 16080978
    [Abstract] [Full Text] [Related]

  • 15. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure.
    Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD.
    Clin Sci (Lond); 2003 Jul 18; 105(1):45-50. PubMed ID: 12639217
    [Abstract] [Full Text] [Related]

  • 16. Role of inflammatory cytokines and chemoattractants in the rat model of streptozotocin-induced diabetic heart failure.
    Drimal J, Knezl V, Navarova J, Nedelcevova J, Paulovicova E, Sotnikova R, Snirc V, Drimal D.
    Endocr Regul; 2008 Sep 18; 42(4):129-35. PubMed ID: 18999900
    [Abstract] [Full Text] [Related]

  • 17. Agents targeting inflammation in heart failure.
    Gullestad L, Kjekshus J, Damås JK, Ueland T, Yndestad A, Aukrust P.
    Expert Opin Investig Drugs; 2005 May 18; 14(5):557-66. PubMed ID: 15926863
    [Abstract] [Full Text] [Related]

  • 18. How to modulate inflammatory cytokines in liver diseases.
    Tilg H, Kaser A, Moschen AR.
    Liver Int; 2006 Nov 18; 26(9):1029-39. PubMed ID: 17032402
    [Abstract] [Full Text] [Related]

  • 19. The importance of tumor necrosis factor and lipoproteins in the pathogenesis of chronic heart failure.
    Sharma R, Al-Nasser FO, Anker SD.
    Heart Fail Monit; 2001 Nov 18; 2(2):42-7. PubMed ID: 12634890
    [Abstract] [Full Text] [Related]

  • 20. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches.
    Gong KZ, Song G, Spiers JP, Kelso EJ, Zhang ZG.
    Int J Clin Pract; 2007 Apr 18; 61(4):611-21. PubMed ID: 17394435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.